The virtual reality training sessions were designed to feature "the same sights, sound and sensations a surgeon would encounter during real procedures." 

Drug-coated balloons were associated with a lower risk of bleeding after PCI than drug-eluting stents, the study's authors reported. 

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

The new algorithm was designed to evaluate a user's heart rhythm while they are still or even sleeping. 

Results from multi-detector CT scans revealed that women in particular appeared to be more susceptible to faster deterioration of the aging aorta.

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.